Literature DB >> 241119

Erythromycin stearate in acute maxillary sinusitis.

O Kalm, C Kamme, B Bergström, T Löfkvist, O Norman.   

Abstract

76 patients with acute maxillary sinusitis were treated with oral erythromycin stearate (500 mg twice or 3 times a day for 10 days). The mean concentration of erythromycin in the sinus secretion after 3-5 days' treatment was 0.6 mug/ml with the lower dosage and 1.3 mug/ml with the higher. The concentration of erythromycin in the sinus secretion was, on the average, 10-20 times higher than the minimum inhibitory concentration (MIC) for group A streptococci and pneumococci, and reached MIC values for 15-30% of 100 examined strains of Haemophilus influenzae. 81% of the patients given the smaller and 94% of those given the larger dose improved or recovered. Radiological improvement was demonstrated in both groups. The infections with H. influenzae tended to respond somewhat less to the treatment than those with pneumococci. Comparisons of the roentgen findings and the findings at aspiration showed good agreement. An extra projection taken with the patient recumbent and the affected side downwards gave no information above that obtained from the routine projections. The large dose caused side effects more often (in 17/41 patients) than the smaller one (4/35 patients). In 10 patients treatment was discontinued because of side effects; 8 of them had received the larger dose.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 241119     DOI: 10.3109/inf.1975.7.issue-3.10

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  5 in total

1.  [Tissue penetration of erythromycin (author's transl)].

Authors:  G A Dette
Journal:  Infection       Date:  1979       Impact factor: 3.553

2.  [Concentrations of erythromycin and amoxicillin in tonsil and sinus tissues of patients with tonsillitis and sinusitis. A comparison (author's transl)].

Authors:  H Blenk; K Simm; B Blenk; G Jahneke
Journal:  Infection       Date:  1982       Impact factor: 3.553

3.  The use of macrolides in respiratory tract infections.

Authors:  J C Pechère
Journal:  Int J Antimicrob Agents       Date:  1993-11       Impact factor: 5.283

4.  [Binding, distribution and efficacy of erythromycin (author's transl)].

Authors:  G A Dette
Journal:  Infection       Date:  1982       Impact factor: 3.553

5.  The penetration of erythromycin into the middle ear.

Authors:  L Sundberg; T Edén; S Ernstson
Journal:  Infection       Date:  1982       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.